Physician profile
Peter David Snell
NPI 1003293622
$5,178.61
in general payments reported to CMS, 2019-2025
27 companies · $1,815 in 2025
The $1,815 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $25.58 · 2021: $232 · 2022: $467 · 2023: $798 · 2024: $1,738 · 2025: $1,815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,287 · Education: $64.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,286.57 |
| Education | $64.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,578.97 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $476.76 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $392.31 | 2022-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $300.30 | 2022-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $292.90 | 2023-2025 | |
| Ardelyx, INC. | $271.13 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $260.48 | 2023-2025 | |
| Lilly USA, LLC | $206.12 | 2023-2025 | Omvoh, Zepbound |
| Qol Medical, LLC | $206.02 | 2024-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $138.13 | 2022-2025 | Ocaliva |
| Pfizer INC. | $138.01 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $133.55 | 2024-2025 | Vowst, Zenpep |
| Celltrion USA INC. | $110.54 | 2024-2025 | Zymfentra, Vegzelma |
| Merck Sharp & Dohme LLC | $109.04 | 2023-2024 | Dificid |
| Mirum Pharmaceuticals, INC. | $105.75 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Micro-Tech Endoscopy USA, INC. | $84.02 | 2024-2025 | Lesionhunter, Snares, Irrigation Tubing |
| Nestle Healthcare Nutrition INC. | $72.68 | 2023 | |
| Madrigal Pharmaceuticals | $58.08 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $52.50 | 2023-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $49.27 | 2024-2025 | Voquezna |
| Evoke Pharma, INC. | $25.90 | 2023-2024 | Gimoti |
| Ferring Pharmaceuticals INC. | $24.85 | 2023 | Rebyota |
| Daiichi Sankyo INC. | $21.43 | 2023 | Injectafer |
| Amgen INC. | $20.12 | 2023 | Avsola, Amjevita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.28 | 2023 | Cyltezo |
| Vivus LLC | $16.63 | 2025 | Pancreaze |
| Ipsen Biopharmaceuticals, INC | $15.84 | 2025 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Snell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.